1. S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL. (23rd June 2022) Authors: Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y.; Manier, S.; Facon, T.; Harrison, S. J.; Er, J.; Volzone, F.; Pinto, A.; Montes, C.; Ocio, E. M.; Alfonso-Pierola, A.; Rodriguez Otero, P.; Offner, F.; Guidetti, A.; Corradini, P.; Titouan, C.; Hulin, C.; Touzeau, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS. (23rd June 2022) Authors: Rodriguez Otero, P.; D'Souza, A.; Reece, D.; van de Donk, N. W.; Chari, A.; Krishnan, A.; Martin, T.; Mateos, M. V.; Morillo, D.; Hurd, D.; Rosinol, L.; Balari, A. S.; Wäsch, R.; Vishwamitra, D.; Wang Lin, S. X.; Prior, T.; Vandenberk, L.; Smit, M.-A. D.; Oriol, A.; Dholaria, B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗